Valuation: Tonix Pharmaceuticals Holding Corp

Market Cap 19Cr 16Cr 15Cr 14Cr 26Cr 1.77TCr 26Cr 176.55Cr 69Cr 883.88Cr 70Cr 68Cr 2.94TCr P/E 2026 *
-1.16x
P/E 2027 * -1.85x
Enterprise Value 19Cr 16Cr 15Cr 14Cr 26Cr 1.77TCr 26Cr 176.55Cr 69Cr 883.88Cr 70Cr 68Cr 2.94TCr EV / Sales 2026 *
5.43x
EV / Sales 2027 * 2.35x
Free-Float
99.86%
Yield 2026 *
-
Yield 2027 * -
03/08 Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
22/07 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
15/07 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
13/07 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
13/07 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
29/06 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
29/06 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
25/06 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
08/06 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
08/06 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
29/05 Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting CI
27/05 Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody CI
26/05 Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment CI

Last Transcript: Tonix Pharmaceuticals Holding Corp

Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer 57 04/02/2025
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.89%+3.20%+59.70%+165.18% 1,06200Cr
-0.24%+0.45%+50.64%+52.02% 62TCr
-0.95%-5.26%+24.23%+65.08% 43TCr
+1.77%+5.12%+49.22%+40.34% 36TCr
+0.92%+0.06%+36.14%+40.99% 29TCr
+1.17%-5.05%+9.53%+10.18% 25TCr
-0.73%+4.44%+42.22%+66.41% 22TCr
+3.78%-0.60%-1.36%-44.17% 20TCr
-0.68%-0.32%+18.66%+66.32% 16TCr
Average +0.93%-1.90%+32.11%+51.37% 39.91TCr
Weighted average by Cap. +0.65%-0.83%+41.14%+78.27%

Financials

2026 *2027 *
Net sales 3.42Cr 2.97Cr 2.78Cr 2.54Cr 4.8Cr 325.64Cr 4.86Cr 32Cr 13Cr 162.7Cr 13Cr 13Cr 541.54Cr 7.89Cr 6.85Cr 6.41Cr 5.87Cr 11Cr 751.92Cr 11Cr 75Cr 29Cr 375.68Cr 30Cr 29Cr 1.25TCr
Net income -17Cr -15Cr -14Cr -13Cr -24Cr -1.62TCr -24Cr -161.58Cr -63Cr -808.95Cr -64Cr -62Cr -2.69TCr -15Cr -13Cr -12Cr -11Cr -21Cr -1.45TCr -22Cr -144.34Cr -57Cr -722.64Cr -57Cr -56Cr -2.41TCr
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-